Undruggables | Kisaco Research

Connecting the experts tasked with making the undruggable druggable

North American Protein Degradation Congress | 16th - 24th February, 2021

Targeting Protein Misfolding Congress | 15th-17th March, 2021

Targeting RNA Congress | 15th - 17th March, 2021

About the Undruggables Portfolio

The Targeting the Undrugged series is focused on developing new drug modalities to target ‘undruggable’ pathways. Recent technological advancements in structural analysis, including techniques such as cryo-electron microscopy and XFEL together with a deeper understanding of the human genome has opened new drug targets for the pharmaceutical industry to investigate. These targets include protein degradation pathways (including ubiquitin and E3 ligases), K-Ras, transcription factors, Amyloid Beta, RNA and even the proteasome.

With significant investment and collaborations increasing rapidly across the undruggable space, no wonder there is a lot of excitement. The community is watching closely, awaiting critical updates for topics as diverse as the first PROTAC clinical trials, drug discovery to target misfolded proteins, epitranscriptomics, platforms for RNA and early results for the first C-Myc modulators. Crucially, everybody is looking out for the next undruggable target. The meetings in the Targeting the Undrugged series will allow you to connect with expert academics, innovative biotechs and leading industry at the translational level. You'll get the chance to discuss the innovations and opportunities, and address the key hurdles, that come with developing new drug discovery platforms such as proof of concept parameters, profiling efficacy, bioavailability and toxicology.

Filter by:
Targeting RNA Congress 2021
15-17 Mar 2021
Virtual Summit
Targeting RNA is set to be the next big thing; 85% of human genome transcribed to RNA but only 3% translated into proteins, therefore making it an obvious target. With Risdiplam being approved by the FDA in August, and several major collaborations also being penned throughout 2020, including a $190 million deal between Arrakis and Roche, it seems like a good time to target these protein precursors. Targeting RNA 2021 will take a look at the latest techniques to analyse and predict protein structure, as well as hearing from leading researchers and industry on how to incorporate learnings from RNA biology into potent and selective ligands to help prevent, rather than treat, disease.
Targeting Protein Misfolding Congress
15-17 Mar 2021
Virtual Summit
With the neurological drug market now worth $86 billion, and the FDA set to reach a decision on Biogen’s Acudanimib in Spring, whether you’re focused on oncology, Alzheimer’s or ALS, it’s an exciting time to be targeting misfolding diseases.Though there are currently no therapies and cures in this area of drug discovery due to several unmet drug discovery needs. The inaugural Targeting Protein Misfolding Congress will bring together academic and industry leaders, such as Anavex, Ionis Pharmaceuticals, Wren Therapeutics, Arizona State University and University of Florida, who are building platforms to identify and validate targets in protein misfolding diseases and intrinsically disordered proteins to combat these challenges:The lack of appropriate disease models, physiological assays and blood biomarkers to evaluate translation aspects and target engagement.Delivery mechanisms to deliver small molecules and biologics across the blood brain barrier.Determining the true drivers and toxic species in protein misfolding diseases. Mapping the druggable hotspots on protein aggregates and intrinsically disordered proteins to target with small molecules.
European Protein Degradation Congress 2021
22-23 Sep 2021
Basel, Switzerland
With deals in the protein degradation market reaching nearly $2 billion and unique degradation ideas coming into play such as LYTACs and ENDTACs, eyes are focused on how much further protein degradation-based therapeutics will continue to growwithin the pharmaceutical industry.Following huge success in September 2020, the 3rd European Protein Degradation Congress, returns to Switzerland 28th-30th September 2021, where you can hear the most up to date and relevant information for the broad range of topics in the field of targetedprotein degradation.New areas will cover novel methods in harnessing E3 ligases and the latest discoveries from PROTACs and molecular glues with preclinical and clinical data being shown.Leading industry players from biotechs and big pharma will come together to exchange thoughts on how to best overcome obstacles to achieving reliable in vitro and in vivo data. Academic experts will be present their latest research to help build a deeper understanding of the mechanisms involved in the Ubiquitin pathway, providing a clearer picture on what makes a good, or not good, target for degradation.
Filter by:
North American Protein Degradation Congress 2021
16-24 Feb 2021
The targeted protein degradation field is expanding, gone are the days of simple proof of concept…. We now have LYTACs, AUTACs and ATTECs as well as numerous PROTAC and Molecular Glue companies with millions of dollars worth of investment. C4 netted $182.4 million in IPO, and Nurix and Kymera closed funding with $120 million and $102 million apiece. With several start-ups launching, including Lycia and Amphista therapeutics, investment in this area is booming, and it’s not slowing down.There are currently over 85 degraders being considered at various stages of development, both preclinical and clinical, as well as in discovery. However, key questions are yet to be answered:How will degrader research translate in the clinic?Why are we still struggling with oral bioavailability?How can we effectively validate novel targets and degrade ‘undruggable’ targets of interest?What can be learned from the new, emerging degrader strategies that are emerging?Once again bringing together leaders from pharma, biotech and academia as well as innovative service providers, the North American Protein Degradation Congress is back to give you the full picture from molecular biology right the way up to the latest in medicinal chemistry and clinical data.Learn to create clinically applicable degraders to the entire proteome at the digital North American Protein Degradation Congress 2021.

Our Network of Thought Leaders

Partnership Opportunities

— Undruggables Partners Include —


The Undruggables portfolio is your global, multi-channel partner to reach, engage and interact with the most influential and important stakeholders in this space.

With a solution to hit every objective, our high-level annual summits, bespoke introductions, reports, webinars and content-driven marketing offer multiple ways engage your target market and can form an integral part of your annual marketing plan.
At Kisaco, we also know that you need different solutions at different times of the year, so our packages can be built to order to fit in with your current plans.

  • Product launch? – If you need to bring a new product to market, you’ll need air-time to make announcements, synchronized marketing and PR announcements to leverage our audiences and media partnerships, as well as access to client accounts to build sales pipelines. We can help!
  • Need to drive leads? Our summits offer best-in-class networking opportunities, giving you access to decision makers to arrange meetings, while our bespoke webinars offer up a chance to get hundreds of leads in one single activity.
  • Want thought leadership? Showcase your expertise by presenting on market-leading programs .
  • Need investment? – Regardless of where you are in your fund-raising journey, we have can help give you the visibility and platform you need to put you in the eyeline of the investor.

Talk to us today to see how we can give you access to the decision makers you need and look at a short, mid or long term marketing plan. E: [email protected]

Partner with Us